Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Hansa Biopharma signed a EUR 115 million imlifidase licensing agreement with SERB Pharmaceuticals for European and MENA rights. The deal preserves Hansa's…
Hansa Biopharma has signed an Idefirix licensing deal with SERB Pharmaceuticals worth up to EUR 115 million, covering exclusive rights to develop and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Hansa Biopharma granted SERB Pharmaceuticals exclusive rights to develop and commercialize IDEFIRIX (imlifidase) across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and MENA for total consideration of €115M (~$128M USD). IDEFIRIX is the first-in-class IgG-cleaving enzyme conditionally authorized in Europe for desensitization of highly sensitized kidney transplant patients with positive crossmatch.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| SERB Pharmaceuticals SA / Hansa Biopharma AB (this deal) | 2026 | $134M | — |
| Horizon Pharma plc / Crealta Holdings LLC | 2015 | $510M | 87 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
| Ipsen S.A. / Memo Therapeutics AG | 2026 | $797M | 66 |
| Novartis AG / Regulus Therapeutics | 2025 | $1.7B | 62 |
| Eli Lilly and Company / Ascidian Therapeutics, Inc. | 2026 | $1.9B | 62 |
| Genzyme Corporation / Bone Care International, Inc. | 2005 | $600M | 61 |
← Browse all deals · How we score deals
More: 2026 deals · Nephrology deals